Cargando…

Osimertinib-Induced Cardiomyopathy

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Shruti R., Brown, Sherry-Ann N., Kubusek, Jilan E., Mansfield, Aaron S., Duma, Narjust
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298525/ https://www.ncbi.nlm.nih.gov/pubmed/34317311 http://dx.doi.org/10.1016/j.jaccas.2019.12.038

Ejemplares similares

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report
por: Fukuda, Yuko, et al.
Publicado: (2022)

Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report
por: Patel, Karishma, et al.
Publicado: (2023)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2021)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
por: Florez (DUMA), Narjust, et al.
Publicado: (2023)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide
por: Abeykoon, Jithma P., et al.
Publicado: (2018)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient
por: Vera-Aguilera, Jesus, et al.
Publicado: (2018)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Enlarging Pancreatic Schwannoma: A Case Report and Review of the Literature
por: Duma, Narjust, et al.
Publicado: (2015)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib
por: González, Iván, et al.
Publicado: (2019)

Correction: Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report
por: Patel, Karishma, et al.
Publicado: (2023)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Osimertinib‐induced severe interstitial lung disease: A case report
por: Fan, Mengdi, et al.
Publicado: (2019)

The State of Cancer Care in Venezuela
por: Duma, Narjust, et al.
Publicado: (2019)

Osimertinib-associated ashy dermatosis–like hyperpigmentation
por: Lertpichitkul, Pattamon, et al.
Publicado: (2020)

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
por: Mohammed, Turab, et al.
Publicado: (2021)

Osimertinib-Induced Unilateral Diffuse Alveolar Hemorrhage in a Patient With Pulmonary Adenocarcinoma
por: Saeki, Shiho, et al.
Publicado: (2021)

COVID-19 and Global Oncology: A Year in Review
por: Desai, Aakash, et al.
Publicado: (2021)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

Osimertinib: Pneumonitis and interstitial lung disease: case report
Publicado: (2022)

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions
por: Sun, Mengyao, et al.
Publicado: (2021)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
por: Xu, Caihua, et al.
Publicado: (2020)

Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma
por: Wong, Andrew K., et al.
Publicado: (2021)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Mangaonkar, Abhishek, et al.
Publicado: (2017)

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
por: Bian, Shuang, et al.
Publicado: (2020)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

A Case of Rapidly Progressive Diabetic Nephropathy Induced by Osimertinib
por: Karasawa, Kazunori, et al.
Publicado: (2023)

Exclusion of Male Patients in Breast Cancer Clinical Trials
por: Duma, Narjust, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_an8g7pdr32nemsg015rqqa5ud4